Capabilities

Strategic investment in Revance Therapeutics, Inc.

Medicis Pharmaceutical Corporation

Our attorneys represented Medicis Pharmaceutical Corporation in connection with research, development, licensing, manufacturing, and other commercial matters, including in strategic investment in Revance Therapeutics, Inc. and the purchase of an option to acquire Revance or to license exclusively in North America Revance's novel topical botulinum toxin type A product under clinical development.

Email Disclaimer